(S,R,S,S) Orlistat - CAS 111466-63-8
Catalog number: 111466-63-8
Molecular Formula:
C29H53NO5
Molecular Weight:
495.75
COA:
Inquire
Description:
An isomeric impurity of Orlistat, which a pancreatic lipase inhibitor acting locally in the gastrointestinal tract to inhibit lipase.
Publictions citing BOC Sciences Products
  • >> More
Purity:
> 95%
Appearance:
White Solid
Synonyms:
[2S-[2α(S*),3β]]-N-Formyl-L-leucine 1-[(3-Hexyl-4-oxo-2-oxetanyl)methyl]dodecyl Ester;
MSDS:
Inquire
Quantity:
Milligrams-Grams
1.Clinician identification of youth abusing over-the-counter products for weight control in a large U.S. integrated health system.
Austin SB1, Penfold RB2, Johnson RL3, Haines J4, Forman S5. J Eat Disord. 2013 Oct 21;1:40. doi: 10.1186/2050-2974-1-40. eCollection 2013.
BACKGROUND: Abuse of over-the-counter (OTC) products, such as diet pills and laxatives, for weight control by adolescents is well-documented and can precipitate serious medical conditions. Yet only a small percentage of youth with disordered weight control behaviors receive treatment. The objective of this study was to examine how often clinicians communicate with youth with symptoms consistent with abuse of OTC products for weight control about possible use of these products. We used electronic medical records and administrative claims for services for 53,229 12 to 17 year old patients receiving care from an integrated health system in the U.S. Northwest from August 2007 to December 2010. We examined electronic text of clinical notes to identify encounters in which the clinician noted one of 10 metabolic conditions potentially associated with abuse of OTC products (diet pills, laxatives, diuretics, ipecac, orlistat, and alli®) for weight control and then assessed whether clinicians noted communication with adolescent patients about possible use of OTC products for weight control.
2.Orlistat 60 mg reduces visceral adipose tissue: a 24-week randomized, placebo-controlled, multicenter trial.
Smith SR1, Stenlof KS, Greenway FL, McHutchison J, Schwartz SM, Dev VB, Berk ES, Kapikian R. Obesity (Silver Spring). 2011 Sep;19(9):1796-803. doi: 10.1038/oby.2011.143. Epub 2011 Jun 30.
It is well established that abdominal obesity or upper body fat distribution is associated with increased risk of metabolic and cardiovascular disease. The purpose of the present study was to determine if a 24 week weight loss program with orlistat 60 mg in overweight subjects would produce a greater change in visceral adipose tissue (VAT) as measured by computed tomography (CT) scan, compared to placebo. The effects of orlistat 60 mg on changes in total fat mass (EchoMRI-AH and BIA), ectopic fat (CT) and glycemic variables were assessed. One-hundred thirty-one subjects were randomized into a multicenter, double-blind placebo controlled study in which 123 subjects received at least one post baseline efficacy measurement (intent-to-treat population). Both orlistat-and placebo-treated subjects significantly decreased their VAT at 24 weeks with a significantly greater loss of VAT by orlistat treated subjects (-15.7% vs. -9.4%, P < 0.05).
3.Multi-factorial approach associated with a new 'on/off' Orlistat® use in a weight loss maintenance programme: 4 years follow-up.
Makoundou V1, Pataky Z, Bobbioni-Harsch E, Gachoud JP, Habicht F, Golay A. Obes Facts. 2011;4(3):191-6. doi: 10.1159/000329409. Epub 2011 May 30.
AIM: To assess the efficacy of a specific long-term programme for weight loss maintenance using a new 'on/off' Orlistat approach in obese subjects who previously lost more than 10% of their body weight.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Chemical Structure

CAS 111466-63-8 (S,R,S,S) Orlistat

Quick Inquiry

Verification code

Featured Items